| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 100mg/4ml |
| Product Type |
Product Size |
| Tablet |
60'S |
| Product Company |
| Pharma Solution |
Sorafenib 500mg |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| PMS Pharma |
Exemastane 25mg |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Martin Dow |
Anastrozole 1mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Searle Pharma |
|
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Content | "
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
| Exemestane is used to treat early breast cancer in women who have experienced menopause ('change of life'; end of monthly menstrual periods). | Anastrozole is a type of hormone treatment. It works by lowering the levels of oestrogen hormones in your body. It is mainly prescribed for women who have been through the menopause and have a type of cancer called hormone-dependent breast cancer. | Rituximab, an anti CD20 monoclonal antibody, is used in the management of lymphoproliferative and autoimmune conditions. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
|
Reviews
There are no reviews yet.